Experience With Rufinamide in a Pediatric Population: A Single Center's Experience

Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric neurology 2010-09, Vol.43 (3), p.155-158
Main Authors: Vendrame, Martina, MD, PhD, Loddenkemper, Tobias, MD, Gooty, Vasu D., MD, Takeoka, Masanori, MD, Rotenberg, Alexander, MD, PhD, Bergin, Ann M., MD, Eksioglu, Yaman Z., MD, Poduri, Annapurna, MD, Duffy, Frank H., MD, Libenson, Mark, MD, Bourgeois, Blaise F., MD, Kothare, Sanjeev V., MD
Format: Article
Language:English
Subjects:
Adolescent
Adult
Anticonvulsants - therapeutic use
Bacterial diseases
Biological and medical sciences
Child
Child, Preschool
Epilepsy - drug therapy
Epilepsy - physiopathology
Female
Human bacterial diseases
Humans
Infant
Infectious diseases
Male
Medical sciences
Neurology
Pediatrics
Retrospective Studies
Seizures - drug therapy
Seizures - physiopathology
Treatment Outcome
Triazoles - therapeutic use
Tuberculosis and atypical mycobacterial infections
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes.
ISSN:0887-8994
1873-5150
DOI:10.1016/j.pediatrneurol.2010.04.003